Inductive Bio

Overview

Inductive Bio is a New York company using data and machine learning models to solve small molecule ADMET problems[1]. The company offers Beacon-1, a class of ADMET AI models trained on a pre-competitive data consortium[2], along with Compass software for running virtual experiments and reviewing predictions, and Indy, an AI chemistry assistant[2]. Inductive Bio claimed three consecutive first place finishes in the world's largest ADMET benchmarks, including an OpenADMET and ExpansionRx blind challenge where Beacon-1 outperformed 370+ submissions across 9 endpoints and 2,250 compounds[3]. The company is leading a $21M ARPA-H initiative with Amgen and top academic institutions to develop AI drug toxicity models[4]. Inductive Bio is supported by investors including a16z and Lux[5]. Its customers include biopharma companies such as Belharra, Augustine Therapeutics, Light Horse Therapeutics, Arrakis, Dewpoint, Gandeeva, Nexo Therapeutics, Rapport and Tenvie[6].

Inductive Bio sold its Beacon-1 class of ADMET AI models trained on a pre-competitive data consortium, Compass software for running virtual experiments and reviewing predictions, and Indy, an AI chemistry assistant. [2]

Business address: 708 3rd Avenue, New York, New York, 10017. [7]

Growth & traction

Inductive Bio claimed three consecutive 1st place finishes in the world's largest ADMET benchmarks, including an OpenADMET and ExpansionRx blind challenge where Beacon-1 outperformed 370+ submissions across 9 endpoints and 2,250 compounds. [3]

Partnerships

Inductive Bio said it is leading a $21M ARPA-H initiative with Amgen and top academic institutions to develop AI drug toxicity models. [4]

Funding history

Inductive Bio said it was supported by leading investors at the intersection of technology and biotechnology, including a16z and Lux. [5]

Customers

Biopharma companies named on Inductive Bio's site among its customers and testimonials included Belharra, Augustine Therapeutics, Light Horse Therapeutics, Arrakis, Dewpoint, Gandeeva, Nexo Therapeutics, Rapport and Tenvie. [6]